Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine

Benjamin Powers; Tuya Pal; Christine Laronga

doi:10.1016/j.soc.2017.08.003

Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine

Surg Oncol Clin N Am. 2018 Jan;27(1):1-22. doi: 10.1016/j.soc.2017.08.003.

Authors

Benjamin Powers¹, Tuya Pal², Christine Laronga³

Affiliations

¹ Department of Breast Oncology, H. Lee Moffitt Cancer Center, 10920 N. Mckinley Drive, Tampa, FL 33612, USA.
² Department of Medicine, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
³ Department of Breast Oncology, H. Lee Moffitt Cancer Center, 10920 N. Mckinley Drive, Tampa, FL 33612, USA. Electronic address: christine.laronga@moffitt.org.

PMID: 29132555
DOI: 10.1016/j.soc.2017.08.003

Abstract

Technological advances realized through next-generation sequencing technologies coupled with the loss of the ability to patent genes have led to reduction in costs for genetic testing. As a result, more people are being identified with inherited breast cancer syndromes that may affect recommendations for surveillance and risk reduction. Surgeons, at the forefront for patients newly diagnosed with breast cancer, must keep current with the changing landscape of genetics to continue to provide appropriate counsel and care. This article provides an overview of individuals at risk for inherited cancer predisposition and recommendations for surveillance and management.

Keywords: Germline mutation; Inherited breast cancer syndromes; Personalized medicine; Surgical considerations.

Publication types

Review

MeSH terms

Breast Neoplasms / diagnosis*
Female
Genetic Predisposition to Disease / genetics*
Humans
Precision Medicine / methods
Precision Medicine / trends*

Supplementary concepts

Breast Cancer, Familial